NuCana (NASDAQ:NCNA) Stock Jumps 0.8% – Time to Buy?

Posted by James Conley on Sep 26th, 2026

NuCana PLC Sponsored ADR (NASDAQ:NCNA – Get Free Report) rose 0.8% on Thursday. The stock traded as high as $1.34 and last traded at $1.32. 9,226 shares changed hands during trading, a decline of 90% from the average daily volume of 88,672 shares. The stock had previously closed at $1.31.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NuCana in a report on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, NuCana presently has a consensus rating of “Sell”.

Check Out Our Latest Stock Report on NCNA

NuCana Trading Down 3.0%

The stock has a market cap of $5.32 million, a P/E ratio of -0.34 and a beta of 2.23. The company’s 50 day moving average price is $1.39 and its two-hundred day moving average price is $1.69.

NuCana (NASDAQ:NCNA – Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($0.99) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.65) by $1.66.

About NuCana

(Get Free Report)

NuCana plc is a clinical-stage biopharmaceutical company focused on developing cancer treatments designed to improve the delivery and activity of nucleoside analog medicines. The company’s proprietary ProTide technology is intended to help overcome biological barriers that can limit the effectiveness of conventional nucleoside-based therapies.

NuCana’s lead investigational product, NUC-3373, is a ProTide-based therapy derived from 5-fluorouracil (5-FU), a commonly used chemotherapy agent.